2616 fundamentals
CSTONE PHARMACEUTICALS financial statements, including revenue, expenses, profit, and loss
The total revenue of 2616 for the last semiannual is 275.42 M HKD, and it's 25.98% higher compared to the previous semiannual. The net income of H1 24 is 17.01 M HKD.
Q3 '17
Q4 '17
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
0.00
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: HKD
Q3 '17
Q4 '17
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
TTM